171 related articles for article (PubMed ID: 36790589)
1. Aldolase B attenuates clear cell renal cell carcinoma progression by inhibiting CtBP2.
Tan M; Pan Q; Wu Q; Li J; Wang J
Front Med; 2023 Jun; 17(3):503-517. PubMed ID: 36790589
[TBL] [Abstract][Full Text] [Related]
2. Aldolase B inhibits metastasis through Ten-Eleven Translocation 1 and serves as a prognostic biomarker in hepatocellular carcinoma.
Tao QF; Yuan SX; Yang F; Yang S; Yang Y; Yuan JH; Wang ZG; Xu QG; Lin KY; Cai J; Yu J; Huang WL; Teng XL; Zhou CC; Wang F; Sun SH; Zhou WP
Mol Cancer; 2015 Sep; 14():170. PubMed ID: 26376879
[TBL] [Abstract][Full Text] [Related]
3. Aldolase B Overexpression is Associated with Poor Prognosis and Promotes Tumor Progression by Epithelial-Mesenchymal Transition in Colorectal Adenocarcinoma.
Li Q; Li Y; Xu J; Wang S; Xu Y; Li X; Cai S
Cell Physiol Biochem; 2017; 42(1):397-406. PubMed ID: 28558381
[TBL] [Abstract][Full Text] [Related]
4. Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing the Aldob/Akt/PP2A protein complex.
He X; Li M; Yu H; Liu G; Wang N; Yin C; Tu Q; Narla G; Tao Y; Cheng S; Yin H
PLoS Biol; 2020 Dec; 18(12):e3000803. PubMed ID: 33275593
[TBL] [Abstract][Full Text] [Related]
5. Accumulation of fructose 1,6-bisphosphate protects clear cell renal cell carcinoma from oxidative stress.
Wang J; Wu Q; Qiu J
Lab Invest; 2019 Jun; 99(6):898-908. PubMed ID: 30760861
[TBL] [Abstract][Full Text] [Related]
6. Fructose-1,6-Bisphosphate Aldolase B Depletion Promotes Hepatocellular Carcinogenesis Through Activating Insulin Receptor Signaling and Lipogenesis.
Liu G; Wang N; Zhang C; Li M; He X; Yin C; Tu Q; Shen X; Zhang L; Lv J; Wang Y; Jiang H; Chen S; Li N; Tao Y; Yin H
Hepatology; 2021 Dec; 74(6):3037-3055. PubMed ID: 34292642
[TBL] [Abstract][Full Text] [Related]
7. High expression of fructose-bisphosphate aldolase A induces progression of renal cell carcinoma.
Huang Z; Hua Y; Tian Y; Qin C; Qian J; Bao M; Liu Y; Wang S; Cao Q; Ju X; Wang Z; Gu M
Oncol Rep; 2018 Jun; 39(6):2996-3006. PubMed ID: 29693182
[TBL] [Abstract][Full Text] [Related]
8. ALDOB represents a potential prognostic biomarker for patients with clear cell renal cell carcinoma.
Shao Y; Wu B; Yang Z; Liu Z; Ma Y; Huang H; Liu Y; Wang Z; Hu W; Wang Y; Niu Y
Transl Androl Urol; 2023 Apr; 12(4):549-571. PubMed ID: 37181232
[TBL] [Abstract][Full Text] [Related]
9. Interaction with CCNH/CDK7 facilitates CtBP2 promoting esophageal squamous cell carcinoma (ESCC) metastasis via upregulating epithelial-mesenchymal transition (EMT) progression.
Zhang J; Zhu J; Yang L; Guan C; Ni R; Wang Y; Ji L; Tian Y
Tumour Biol; 2015 Sep; 36(9):6701-14. PubMed ID: 25820824
[TBL] [Abstract][Full Text] [Related]
10. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
[No Abstract] [Full Text] [Related]
11. Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and pentose phosphate pathways.
Li M; He X; Guo W; Yu H; Zhang S; Wang N; Liu G; Sa R; Shen X; Jiang Y; Tang Y; Zhuo Y; Yin C; Tu Q; Li N; Nie X; Li Y; Hu Z; Zhu H; Ding J; Li Z; Liu T; Zhang F; Zhou H; Li S; Yue J; Yan Z; Cheng S; Tao Y; Yin H
Nat Cancer; 2020 Jul; 1(7):735-747. PubMed ID: 35122041
[TBL] [Abstract][Full Text] [Related]
12. Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis.
Peng SY; Lai PL; Pan HW; Hsiao LP; Hsu HC
Oncol Rep; 2008 Apr; 19(4):1045-53. PubMed ID: 18357395
[TBL] [Abstract][Full Text] [Related]
13. ALDOB acts as a novel HBsAg-binding protein and its coexistence inhibits cisplatin-induced HepG2 cell apoptosis.
Wu J; Dan C; Zhao HB; Xiao CX; Liu YP; Si LJ; Ren JL; Guleng B
Crit Rev Eukaryot Gene Expr; 2014; 24(3):181-91. PubMed ID: 25072145
[TBL] [Abstract][Full Text] [Related]
14. Dual effects of fructose on ChREBP and FoxO1/3α are responsible for AldoB up-regulation and vascular remodelling.
Cao W; Chang T; Li XQ; Wang R; Wu L
Clin Sci (Lond); 2017 Feb; 131(4):309-325. PubMed ID: 28007970
[TBL] [Abstract][Full Text] [Related]
15. TRIM33 Overexpression Inhibits the Progression of Clear Cell Renal Cell Carcinoma In Vivo and In Vitro.
Xu Y; Wu G; Zhang J; Li J; Ruan N; Zhang J; Zhang Z; Chen Y; Zhang Q; Xia Q
Biomed Res Int; 2020; 2020():8409239. PubMed ID: 32908919
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 expression is epigenetically repressed in sporadic ovarian cancer cells by overexpression of C-terminal binding protein 2.
May T; Yang J; Shoni M; Liu S; He H; Gali R; Ng SK; Crum C; Berkowitz RS; Ng SW
Neoplasia; 2013 Jun; 15(6):600-8. PubMed ID: 23730208
[TBL] [Abstract][Full Text] [Related]
17. Novel long noncoding RNA OTUD6B-AS1 indicates poor prognosis and inhibits clear cell renal cell carcinoma proliferation via the Wnt/β-catenin signaling pathway.
Wang G; Zhang ZJ; Jian WG; Liu PH; Xue W; Wang TD; Meng YY; Yuan C; Li HM; Yu YP; Liu ZX; Wu Q; Zhang DM; Zhang C
Mol Cancer; 2019 Jan; 18(1):15. PubMed ID: 30670025
[TBL] [Abstract][Full Text] [Related]
18. CtBP2 interacts with TGIF to promote the progression of esophageal squamous cell cancer through the Wnt/β‑catenin pathway.
Ju Q; Jiang M; Huang W; Yang Q; Luo Z; Shi H
Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34878149
[TBL] [Abstract][Full Text] [Related]
19. microRNA-133a exerts tumor suppressive role in oral squamous cell carcinoma through the Notch signaling pathway via downregulation of CTBP2.
Liu W; Shi X; Wang B
Cancer Gene Ther; 2022 Jan; 29(1):62-72. PubMed ID: 33531645
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of miR-181a in clear cell renal cell carcinoma is associated with lower KLF6 expression, enhanced cell proliferation, accelerated cell cycle transition, and diminished apoptosis.
Lei Z; Ma X; Li H; Zhang Y; Gao Y; Fan Y; Li X; Chen L; Xie Y; Chen J; Wu S; Tang L; Zhang X
Urol Oncol; 2018 Mar; 36(3):93.e23-93.e37. PubMed ID: 29066014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
